Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations

Leukemia and Lymphoma

Volumn 48, Issue 12, 2007, Pages 2418-2423

  Scholl, Sebastian ^a   Melle, Christian ^a   Bleul, Annett ^a   Spies Weisshart, Baerbel ^a   Kunert, Christa ^a   Höffken, Klaus ^a   Von Eggeling, Ferdinand ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

AML; FLT3 ITD; Proteomics; SELDI TOF

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD135 ANTIGEN; FLT3 INTERNAL TANDEM DUPLICATIONS; FLT3 TYROSINE KINASE DOMAIN; GENE PRODUCT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CELL ISOLATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STRUCTURAL PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WILD TYPE;

ADULT; AGED; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM REPEAT SEQUENCES;

EID: 37149042891     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701671036     Document Type: Article

References (16)

1. Mrózek, K., Heerema, N. A. and Bloomfield, C. D. (2004) Cytogenetics in acute myeloid leukemia. Blood Rev, 18, pp. 115-136.
2. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R. and Pasqualucci, L. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med, 352, pp. 254-266.
3. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S. and Kashima, K. (1996) Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia, 10, pp. 1911-1918.
4. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C. and Martelli, M. F. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, pp. 3733-3739.
5. Dohner, K., Schlenk, R. F., Habdank, M., Scholl, C., Rucker, F. G. and Corbacioglu, A. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood, 106, pp. 3740-3746.
6. Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E. and Belton, A. A. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, pp. 1752-1759.
7. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U. and Platzbecker, U. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, pp. 4326-4335.
8. Kiyoi, H., Ohno, R., Ueda, R., Saito, H. and Naoe, T. (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene, 21, pp. 2555-2563.
9. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y. and Miyawaki, S. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, pp. 2434-2439.
10. Abu-Duhier, F. M., Goodeve, A. C., Wilson, G. A., Care, R. S., Peake, I. R. and Reilly, J. T. (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol, 113, pp. 983-988.
11. Frohling, S., Schlenk, R. F., Breitruck, J., Benner, A., Kreitmeier, S. and Tobis, K. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics. a study of the AML Study Group Ulm. Blood, 100, pp. 3472-4380.
12. Cui, J. W., Wang, J., He, K., Jin, B. F., Wang, H. X. and Li, W. (2004) Proteomic analysis of human acute leukemia cells: Insight into their classification. Clin Cancer Res, 10, pp. 6887-6896.
13. Balkhi, M. Y., Trivedi, A. K., Geletu, M., Christopeit, M., Bohlander, S. K. and Behre, H. M. (2006) Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene, 25, pp. 7041-7058.
14. Scholl, S., Krause, C., Loncarevic, I. F., Muller, R., Kunert, C. and Weding, U. (2005) Specific detection of FLT3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. J Lab Clin Med, 145, pp. 295-304.
15. Grundler, R., Miething, C., Thiede, C., Peschel, C. and Duyster, J. (2005) FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood, 105, pp. 4792-4799.
16. Mizuki, M., Schwable, J., Steur, C., Choudhary, C., Agrawal, S. and Sargin, B. (2003) Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101, pp. 3164-3173.